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BACKGROUND. The objective of the current study was to evaluate in a multicenter
setting the feasibility and efficacy of a high-dose sequential (HDS) chemotherapy
regimen that combined intensive debulking and high-dose therapy (HDT) with
peripheral blood progenitor cell (PBPC) autografting in patients with refractory or
recurrent Hodgkin lymphoma (HL).
METHODS. Data were collected from 102 patients with HL who were treated with
the HDS regimen at 14 centers associated with the Intergruppo Italiano Linfomi.
Twenty-four patients had primary refractory HL, 59 patients had their first recur-
rence of HL (within 1 year in 32 patients and  1 year in 27 patients), and 19
patients had multiple disease recurrences. The HDS regimen included the sequen-
tial delivery of high-dose (hd) cyclophosphamide with PBPC harvesting, metho-
trexate, etoposide, then HDT (usually hd mitoxantrone plus L-phenylalanine mus-
tard) with PBPC autografting. In addition, radiotherapy was delivered to 36
patients at sites of bulky or persistent disease.
RESULTS. Ninety-two patients (90%) completed the HDS program. There were five
toxic deaths (treatment-related mortality rate, 4.9%) and six secondary malignan-
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cies (five patients developed myelodysplastic syndrome/acute myelogenous leu-
kemia, and one patient developed colorectal carcinoma). At a median follow-up of
5 years, the 5-year overall survival (OS) and event-free survival (EFS) projections
were 64% (95% confidence interval [95% CI], 54 –74%) and 53% (95% CI, 43– 63%),
respectively. Patients with their first recurrence had the most favorable outcome,
with 5-year OS and EFS projections of 77% (95% CI, 66 – 88%) and 63% (95% CI,
50 –76%), respectively. There were no significant differences between patients with
early first recurrence and late first recurrence. The poorest outcome was observed
in patients with refractory HL, with 5-year OS and EFS projections of 36% (95% CI,
16 –55%) and 33% (95% CI, 14 –52%), respectively. Patients who received HDS
chemotherapy after multiple recurrences had an intermediate outcome. Multivar-
iate analysis showed that refractory disease and systemic symptoms at the time of
initial presentation were associated significantly associated with poor OS and EFS.
CONCLUSIONS. The use of HDS chemotherapy for patients with refractory and/or
recurrent HL is feasible at the multicenter level. The combination of intensive
debulking and HDT with PBPC autografting offers a good chance of prolonged
disease free survival for patients with their first recurrence of HL. Cancer 2003;97:
2748 –59. © 2003 American Cancer Society.
DOI 10.1002/cncr.11414
KEYWORDS: Hodgkin lymphoma, high-dose chemotherapy, peripheral blood progen-
itor cell autograft, clinical outcome, multicenter trial.
H igh-dose therapy (HDT) plus autotransplantationis now a widely employed procedure for the treat-
ment of patients with refractory or recurrent Hodgkin
lymphoma (HL) after they receive radiotherapy or
conventional-dose chemotherapy.1–3 One randomized
study and several nonrandomized, single-institution
studies showed that these patients had a better out-
come after HDT compared with patients who received
conventional-dose treatments.4 –10 Those findings are
supported further by registry-based, retrospective
studies.11–14
The applicability and efficacy of HDT have been
improved by autografting mobilized peripheral blood
progenitor cells (PBPCs),15,16 and preliminary results
indicate that this also is beneficial for patients with
HL.17 In addition, intensive, prior chemotherapy de-
bulking seems to increase the probability of long-term
survival. A recent two-step, comprehensive program
that includes intensive debulking, PBPC collection,
and final HDT with autotransplantation has been em-
ployed successfully in patients with recurrent and/or
refractory HL.18 Patients entering that program had a
long-term survival projection of 73%, which compares
favorably with the results reported to date with HDT.
A similar approach with debulking chemotherapy fol-
lowed by autotransplantation was employed by the
French Lymphoma Study Group and yielded satisfac-
tory results in patients who completed the program.19
The high-dose sequential (HDS) chemotherapy
regimen is a comprehensive approach that includes
an intensified debulking phase through the sequential
administration of high-dose (hd) cyclophosphamide,
methotrexate, and etoposide followed by au-
tograft.15,20 The scheme takes advantage of the usually
large amounts of PBPCs that can be collected after hd
cyclophosphamide.15,21 HDS chemotherapy was de-
veloped several years ago by the Milan group, who
conducted a single-center study in patients with HL
who failed to respond to conventional therapy.22 HDS
chemotherapy was effective, particularly in patients
with their first episode of recurrent disease.22,23
The original HDS regimen and its modified ver-
sions have been employed widely in the last decade in
Italy for the management of both patients with HL and
patients with non-Hodgkin lymphoma.24 –28 This
prompted us to undertake a retrospective assessment
of the use of HDS chemotherapy as salvage therapy for
patients with HL at centers that belong to the Inter-
gruppo Italiano Linfomi (IIL) organization. The objec-
tives of this study were to evaluate 1) the applicability
of HDS chemotherapy in a multicenter setting, 2) its
tolerability and efficacy in patients with HL who fail to
respond to conventional therapy, and 3) differences in
outcome according to disease status at the time pa-
tients received salvage treatment.
MATERIALS AND METHODS
Patients
The IIL is an Italian organization that was set up to
coordinate and collect data from multicenter study
groups working in the field of lymphoma. It has re-
cently collected retrospective data from 14 Italian cen-
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ters on 102 patients who received the original HDS
regimen as salvage treatment for refractory or recur-
rent HL between January 1993 and September 2000.
Six centers contributed to the study by reporting the
majority of patients (83 of 102 patients; 81%), and 8
smaller centers reported the remaining 19 patients.
The common eligibility criteria were age younger than
60 years; no major organ dysfunction for causes un-
related to HL, including 1) normal cardiac function
(systolic ejection fraction  50%), 2) no chronic respi-
ratory disease, 3) no more than 2.5 times the upper
limit of normal for liver and renal function tests, 4) no
psychiatric disease, and 5) a negative human immu-
nodeficiency virus test; and the ability to provide writ-
ten, informed consent, which was provided by all pa-
tients before they started the program. A poor
performance status or failure to respond to conven-
tional chemotherapy were not exclusion criteria. In 11
centers that reported 98 of 102 patients, HDS chemo-
therapy was the standard treatment for all patients
with HL who were younger than 60 years and pre-
sented with refractory or recurrent disease.
Disease persistence or recurrence was proven by
biopsy or fine-needle aspiration biopsy (57 patients)
or was demonstrated unequivocally on radiographic
studies. Refractory disease was defined as stable or
progressive disease or a tumor reduction  50%, and
partial remission (PR) was defined as a reduction
 50% in the greatest tumor dimension for all known
sites with no new disease sites after completion of the
induction treatment. Recurrence was defined as re-
current HL after a documented complete remission
(CR) that lasted at least 1 month after induction.
Overall, 24 patients had refractory disease after
first-line therapy; 59 patients had their first recurrence
(32 patients within the first 12 months after first-line
therapy and 27 patients  12 months after first-line
therapy: median, 24 months; range, 13–156 months)
after achieving CR. The other 19 patients received
HDS chemotherapy after multiple recurrences. Ac-
cording to the Revised European–American classifica-
tion of lymphoid neoplasms, the histologic subtypes
included nodular sclerosis (68.5%), mixed cellularity
(19%), lymphocyte depletion (7.5%), and lymphocyte
predominance (5%).29
All patients had their disease staged according to
the Cotswold modification of the Ann Arbor system.30
Their main characteristics at the time they started the
HDS regimen, along with their previous treatments,
are summarized in Table 1. Most patients had received
either doxorubicin, bleomycin, vinblastine, and dacar-
bazine (ABVD) or multiple-drug regimens, such as
nitrogen mustard, vincristine, procarbazine, and pred-
nisone (MOPP) plus ABVD or MOPP plus epirubicin,
bleomycin, and vincristine plus cyclophosphamide,
doxorubicin, and dacarbazine (EBV/CAD).31–34
Treatment Plan
The HDS regimen is a comprehensive program that
includes a high-dose (hd) chemotherapy phase with
peripheral blood progenitor cell (PBPC) harvesting
and a final myeloablative treatment with PBPC au-
tografting.15,20 The hd phase includes the sequential
administration at 10-day to 15-day intervals of hd
cyclophosphamide (CY; 7 g/m2), hd methotrexate (8
g/m2), and hd etoposide (VP16; 2 g/m2); granulocyte-
colony stimulating factor is given daily at a dose of 5
mcg/kg after both CY and VP16 to reduce hematologic
toxicity and to expand the circulating progenitor cell
pool. PBPC harvesting is scheduled after CY, and a
second harvest is performed after VP16 in patients
who have inadequate PBPC collection after they re-
ceive CY. Patients with bone marrow (BM) involve-
ment receive a modified schedule with inversion of
the CY/VP16 sequence and PBPC collection at the end
of the hd phase; this modification was designed to
exploit a kind of in vivo purging effect from chemo-
therapy prior to harvests.
Ninety-two of 102 patients (90%) completed the
program with the final myeloablative treatment and
the autograft. The median time between the beginning
of sequential chemotherapy and the autograft was 3
months (range, 2– 8 months). Seventy-nine patients
(86%) were conditioned with the mitoxantrone/L-phe-
nylalanine mustard (L-PAM) combination (i.e., mito-
xantrone 60 mg/m2 on Day 5, L-PAM 180 mg/m2 on
Day 2, and autograft on Day 0).35 Thirteen patients
(14%) received other regimens: carmustine, etoposide,
cytarabine, and melphalan (BEAM; n  10 patients);
L-PAM 180 mg/m only (n  2 patients); or thiotepa/
L-PAM (n  1 patient).5 The decision to use condi-
tioning regimens other than the mitoxantrone/L-PAM
combination was made at the discretion of treating
physicians in the different centers based on the exper-
tise of each center on a given scheme and in the
absence of any documented superiority of one regi-
men over the others.
All patients had an indwelling central venous
catheter. The entire pretransplantation program was
carried out in ordinary, unprotected rooms. Autograft-
ing was conducted in a dedicated inpatient BM trans-
plantation unit. During pancytopenia and after au-
tografting, patients were managed with a common
protocol for prophylaxis comprised of oral antibiotics
(usually ciprofloxacin 500 mg three times daily, flu-
conazole 150 mg intravenously, and acyclovir 250 mg.
three times daily). In the event patients developed
fever  38 °C, blood cultures and chest X-rays were
2750 CANCER June 1, 2003 / Volume 97 / Number 11
taken, and patients were treated empirically with in-
travenous, broad-spectrum antibiotics. Vancomicin
was added only if a surveillance culture documented
the presence of methicillin-resistant, gram positive
cocci; if the fever was of undetermined origin and
persisted after 36 – 48 hours, then intravenous imi-
penem was introduced, and intravenous amphoteri-
cin was added if the fever persisted for another 36 – 48
hours. Antibiotics were continued until the tempera-
ture reverted to normal for at least 48 hours and the
absolute neutrophil count to reverted  500/L. Irra-
diated, leukocyte-filtered, single-donor platelet con-
centrates or, less frequently, multiple-donor, irradi-
ated platelet concentrates were given to patients with
platelet counts  20,000/L; and irradiated, leuko-
cyte-filtered, packed red blood cells were given to
patients with hemoglobin levels  8 g/dL. Prophylaxis
with cotrimoxazole twice per week plus acyclovir was
maintained for 6 months after the autograft.
Radiotherapy was scheduled for patients with
sites of bulky or persistent disease approximately 2
months after autograft. Overall, 36 patients received
radiotherapy, including 35 patients who received ra-
diotherapy as postautograft consolidation and 1 pa-
tient who received radiotherapy for debulking prior to
autograft.
Response and Long-Term Outcome Assessment
Patients had their disease restaged once before the
autograft and again within 2 months after HDS che-
motherapy using common laboratory tests, radiologic
examinations, and BM biopsy. A restaging procedure
was scheduled every 6 months for the first 3 years and
annually thereafter. Computed tomography (CT)
TABLE 1
Main Characteristics of Patients who Received High-Dose Sequential Chemotherapy According to Disease Status Subgroups
Parameter
Patient subgroup
Total (%)Refractory
First recurrence
Later than
first recurrence
CR < 12
months
CR > 12
months
No. of patients 24 32 27 19 102
Gender
Male 8 15 20 12 55 (54)
Female 16 17 7 7 47 (46)
Age (yrs)
Median (range) 27 27 36 37 32
Range 13–60 16–59 18–60 17–58 13–60
Ann Arbor stage
I–II 13 13 12 4 42 (41)
III–IV 11 19 15 15 60 (59)
B symptoms 15 8 8 12 43 (42)
Elevated LDH level 7 6 2 4 19 (19)
BM involvementa 0 3 5 3 11 (11)
Bulky diseaseb 12 8 4 6 30 (29)
Performance status  2c 6 4 1 3 14 (14)
No. of extralymph node sites
None 16 22 14 10 62 (61)
1 7 7 8 8 30 (29)
 2 1 3 5 1 10 (10)
Previous RT 4 18 16 11 49 (48)
First-line therapy
ABVD 12 8 6 2 28 (27)
MOPP 0 0 0 1 1 (1)
Seven or eight-drug regimen 12 22 14 10 58 (57)
Other protocols 0 2 4 5 11 (11)
RT only 0 0 3 1 4 (4)
CR: complete remission; LDH: lactate dehydrogenase; BM: bone marrow; RT: radiotherapy; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP: nitrogen mustard, vincristine, procarbazine, and
prednisone.
a Bone marrow involvement.
b Bulky disease: a mediastinal mass with a width greater than one-third of the greatest transthoracic dimension or a nonmediastinal lymph node disease greater than 10 cm in cross section.
c Defined according to the Eastern Cooperative Oncology Group grading system.
Rescue with HD Chemotherapy in HL/Tarella et al. 2751
scans of the chest and abdomen were performed rou-
tinely, and a second radiologic assessment (e.g., Gal-
lium scan or nuclear magnetic resonance imaging)
was done only in patients who had a residual, suspi-
cious mass on CT scan. BM biopsy was repeated only
for patients with previously detected BM disease in-
volvement. The response criteria are described above.
The two patients who were diagnosed with an unde-
fined CR at the end of HDS chemotherapy were in-
cluded either among the CR group or the PR group,
depending on their status at the first subsequent re-
staging.
Statistical Analysis
All patients were evaluated. The proportions of pa-
tients with given characteristics were compared
among subgroups, with statistically significance dif-
ferences tested using the Fisher exact test. In addition,
the influence of disease status on treatment feasibility
and on the achievement of CR was evaluated with the
Fisher exact test.
Follow-up was updated in December 2002, and all
living patients had been observed at least once in the
previous 6 months. Overall survival (OS) was calcu-
lated from the start of HDS chemotherapy to the date
of death or last follow-up. Event-free survival (EFS)
was measured from the start of HDS chemotherapy
until the first event (death from any cause, recurrence,
or occurrence of a second neoplasm) or last follow-up.
The actuarial durations of OS and EFS were plotted as
curves according to the Kaplan–Meier product-limit
method.36 Differences in OS and EFS according to
disease status were evaluated, including refractory
disease versus recurrent disease (refractory disease vs.
first recurrence vs. later than first recurrence) and the
duration of first CR (12 months vs.  12 months).
Differences in OS also were evaluated according to
whether patients achieved CR after the hd phase, prior
to autograft. Differences in survival between groups
were identified using a generalized log-rank analysis.37
All P values were two-sided, and the cut-off value for
significance was P  0.05. Several clinical variables at
the time patients received HDS chemotherapy were
evaluated in a univariate analysis for possible prog-
nostic significance, including age (younger than 40
years or older than 40 years), gender, disease stage, B
symptoms, BM involvement, bulky disease, extra-
lymph node sites, prior radiotherapy, and disease sta-
tus. Patients also were evaluated in a multivariate
analysis using a stepwise Cox regression model.38
RESULTS
Feasibility and Response
The HDS schedule was feasible at the multicenter
level. Table 2 shows that 92 of 102 patients (90%)
completed the program. Interruptions were due to
1) no response or disease progression in six patients, 2)
insufficient PBPC or BM harvests in two patients, 3)
pulmonary mycotic infection one patient, and 4) pa-
tient refusal in one patient. There were no significant
differences in feasibility among the disease status sub-
groups, as shown in Table 2.
PBPC mobilization was evaluable in 101 patients:
It was satisfactory ( 2  106 harvested CD34 positive
cells per kg) in 89 patients (88%), low in 8 patients, and
absent in 4 patients. Overall, the median value of
harvested CD34 positive cells per kg was 6.9  106
cells/kg (range, 1– 69 cells/kg). Autograft was per-
TABLE 2
Response to High-Dose Sequential Chemotherapy Program According to Disease Status Subgroups
Parametera
Patient subgroup: No. of patients (%)
Total (%)Refractory
First recurrence
Later than
first recurrence
CR < 12
months
CR > 12
months
No. of patients 24 32 27 19 102
HDS completion 21 (87) 30 (94) 24 (89) 17 (89) 92 (90)
CR 10 (42) 25 (78) 24 (89) 14 (74) 73 (71.5)b
PR 5 (21) 2 (6) 2 (7) 2 (11) 11 (10.8)
NR or progression 7 (29) 4 (13) 0 (0) 2 (11) 13 (12.7)
Toxic deathc 2 (8) 1 (3) 1 (4) 1 (5) 5 (4.9)
CR: complete remission; HDS: high-dose sequential chemotherapy; PR: partial remission; NR: no response.
a Response refers to the clinical assessment at the end of the whole program, including consolidation radiotherapy, which was delivered to 36 patients.
b Sixty-nine patients (68%) already were in CR by the end of chemotherapy, and 4 more patients reached CR after consolidation radiotherapy.
c Toxic deaths were due to heart failure in one patient and pneumonia in four patients (caused by aspergillosis in two patients, cytomegalovirus in one patient, and an unidentified agent in the fourth patient).
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formed with PBPCs in 82 patients (80.4%), with PBPCs
and BM cells in 8 patients (7.8%), and with BM cells in
2 patients (1.9%).
All patients were evaluated for response and long-
term outcome in an intent-to-treat analysis. Details of
the response to HDS chemotherapy are reported in
Table 2. Overall, 73 patients (72%) achieved CR, and 24
patients (23.6%) had a poor response, including PR, no
response, and disease progression. Patients with re-
fractory disease had a significantly lower CR rate (42%)
compared with patients in the other subgroups (74 –
89%; P  0.0022).
Overall, 69 patients (68%) already had achieved
CR by the end of chemotherapy, and 4 more patients
reached CR after consolidation radiotherapy. Only two
patients were categorized with an undefined CR at the
end of the program: One patient had a stable CR and
was included in the CR group, and the second patient
had early disease progression at 5 months after receiv-
ing HDS chemotherapy and was included in the
PR/no response group.
Toxicity
There were five toxic deaths (Table 2), which were due
to heart failure in one patient 8 months after autograft
and to pneumonia in four patients that was caused by
aspergillosis in two patients, cytomegalovirus in one
patient, and an unidentified agent in the fourth pa-
tient. These infections manifested during the hd phase
in two patients and occurred 1 month and 5 months
after autograft in the other two patients.
Hematopoietic recovery and transfusion require-
ments after hd CY, hd VP16, and autograft are sum-
marized in Table 3. There were some episodes of
Grade 3– 4 extrahematologic, early, nonfatal toxicity
(other than oral and gastrointestinal mucositis during
the myeloablative phase), including 10 episodes of
pneumonia; 5 episodes of liver toxicity, 14 septic epi-
sodes, 2 episodes of hemorrhagic cystitis, 1 episode of
supraventricular tachyarrhythmia, 1 episode of atrial
fibrillation, and 1 episode of neurologic toxicity. Over-
all, 55% of these episodes were recorded during the
debulking hd phase, and 45% of episodes were re-
corded during the final myeloablative phase. No dif-
ferences in toxicity were observed between the sub-
groups.
Finally, 6 patients developed a secondary malig-
nancy: Four of them developed refractory anemia with
blast excess at 13 months, 20 months, 24 months, and
26 months after the completion of HDS chemother-
apy; and 1 patient developed acute myeloblastic leu-
kemia (AML) 6 months after autograft. Four of these
patients received HDS chemotherapy for either pri-
mary refractory disease (one patient) or first recur-
rence (three patients); the fifth patient received HDS
chemotherapy after a third recurrence and multiple
chemoradiotherapy treatments. One other patient,
who received HDS chemotherapy after his second re-
currence, developed colorectal carcinoma 6 years after
HDS chemotherapy. All patients who developed sec-
ondary malignancies had been exposed to radiother-
apy either as part of their first-line treatment or at the
time they were diagnosed with recurrent disease. In
addition, four patients received further treatment after
HDS chemotherapy due to disease recurrence. Four of
these six patients died of complications related to
their secondary malignancy.
Long-Term Outcome
At the closing date of this analysis, 63 patients were
alive (54 patients without signs of disease or severe
treatment-related complications), 36 patients had
died, and 3 patients had been lost to follow-up. Other
than the 5 treatment-related fatalities, 26 deaths were
related to disease progression, 4 deaths were related to
secondary malignancies, and there was 1 more late
death after 3 years due to unknown causes. At a me-
dian follow-up of 5 years, the actuarial OS and EFS
curves for the entire group had 5-year projections of
64% (95% confidence interval [95% CI], 54 –74%) and
53% (95% CI, 43– 63%), respectively.
Long-term outcome was evaluated according to
disease status at the start of HDS chemotherapy. The
TABLE 3
Hematologic Toxicity during Delivery of High-Dose Sequential
Chemotherapy
Parameter
Median (range)
After
CY 7 g/m2
After
VP16 2 g/m2 Autograft
No. of patients 80 80 92
Days with ANC  500 mL 5 (0–11) 5 (0–10) 8 (5–25)
RBC Tx
Patients receiving Tx (%) 42 37 93
No. of units received 2 (1–6) 2 (1–6) 3 (1–10)
Plts Tx
Patients receiving Tx (%) 36 16 98
No. of units received 2 (1–11) 2 (1–38) 2 (1–24)
Patients with fever (%) 39 47 83
Patients with severe
infections (%)a 8 6 14
Patients with Grade 3–4
mucositis (%) 3 2 32
CY: cyclophosphamide; VP16: etoposide: ANC: absolute neutrophil count; RBC Tx: red blood cell
transfusion; Plts Tx: platelet transfusion.
a Severe infections included 10 patients with of pneumonia, 16 septic episodes, and 2 patients with
hemorrhagic cystitis.
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median follow-up for all subgroups varied between 4.7
years and 5.3 years. The actuarial OS and EFS curves
for the three main subgroups (patients with refractory
disease, patients with their first episode of recurrent
disease, and patients with two or more episodes of
recurrent disease) are shown in Figures 1 and 2. The
5-year OS projections were 36% (95% CI, 16 –55%) for
patients with refractory disease, 77% (95% CI, 66 – 88)
for patients with their first episode of recurrent dis-
ease, and 59% (95% CI, 36 – 84%) for patients with  2
episodes of recurrent disease. The 5-year EFS projec-
tions were 33% (95% CI, 14 –52%) for patients with
refractory disease, 63% (95% CI, 50 –76%) for patients
with their first episode of recurrent disease, and 47%
(95% CI, 24 – 69%) for patients with  2 episodes of
recurrent disease. Patients with refractory disease had
a significantly poorer outcome in terms of both OS (P
 0.003) and EFS (P  0.009) compared with the other
two main subgroups.
There were no significant differences between pa-
tients who were treated for early (within 1 year) or late
( 1 year) first recurrence. The respective actuarial
5-year OS projections were 77% (95% CI, 62–92%) and
77% (95% CI, 60 –93%), respectively; and the actuarial
5-year EFS projections were 69% (95% CI, 52– 85%)
and 56% (95% CI, 35–77%).
Finally, long-term outcome was evaluated accord-
ing to disease status after hd chemotherapy prior to
autograft, i.e., patients who achieved CR (n  42 pa-
tients) and patients who did not achieve CR, including
36 patients who had a PR and 14 patients who had no
response. Figure 3 shows that significant differences
were observed in the OS curves, with actuarial 5-year
projections of 88% (95% CI, 65–97%) for patients who
achieved CR compared with 58% (95% CI, 41–76%) for
patients who had a PR (P  0.01) and 13% (95% CI,
0 –36%) for patients who had no response (P 0.0002).
Analogous differences were observed in the EFS, with
5-year projections of 78% (95% CI, 65–91%) for pa-
tients who achieved CR, 41% (95% CI, 23–59%) for
patients who had a PR (P  0.0007), and 7% (95% CI,
0 –20%) for patients who had no response (P 0.0001),
as shown in Figure 4. No significant differences were
FIGURE 1. Estimated overall survival according to disease status at the time
patients receive high-dose sequential chemotherapy. Patients with refractory
disease had a significantly poorer outcome compared with patients in the two
other main subgroups (patients with their first episode of recurrent disease and
patients with two or more episodes of recurrent disease; P  0.003)
FIGURE 2. Estimated event-free survival according to disease status at the
time patients received high-dose sequential chemotherapy. Patients with re-
fractory disease had a significantly poorer outcome compared with patients in
the two other main subgroups (patients with their first episode of recurrent
disease and patients with two or more episodes of recurrent disease; P
 0.009)
FIGURE 3. Estimated overall survival according to disease status after
patients received high-dose chemotherapy prior to autograft comparing pa-
tients who achieved complete remission (n  42 patients) with patients who
achieved partial remission (n 36 patients) and patients who had no response
(n  14 patients). Patients who achieved complete remission had a signifi-
cantly better outcome compared with patients who achieved partial remission
(P  0.01) and patients who had no response (P  0.0002).
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observed between patients who received autografts
after mitoxantrone/L-PAM and patients who received
other conditioning regimens.
Prognostic Parameters
Several clinical characteristics at the time patients re-
ceived HDS chemotherapy were evaluated for their
prognostic value on OS and EFS in a univariate anal-
ysis. Table 4 shows that two variables—primary refrac-
tory disease and B symptoms—at the time patients
started HDS chemotherapy were associated with poor
OS and EFS. These two variables had independent,
adverse prognostic value in a multivariate analysis
(Table 5).
DISCUSSION
HDT with autograft is considered the treatment of
choice for patients younger than 60 years with HL who
experience primary failure after conventional induc-
tion therapy. A debulking treatment usually is deliv-
ered prior to autograft. Indeed, a status in remission
before autografting is regarded as a very favorable
prognostic factor. However, it remains uncertain
whether short or prolonged debulking therapy and
conventional or intensive debulking therapy should be
included in the salvage program. To address this issue,
the current retrospective study was conducted based
on data provided by 14 Italian centers using the HDS
regimen as rescue therapy for patients with HL. This
well-established regimen is comprised of intensive de-
bulking with sequential hd drug delivery followed by
HDT with PBPC autografting. The results of the cur-
rent study demonstrate 1) the feasibility of using HDS
chemotherapy in a multicenter setting; 2) a high CR
rate and prolonged OS; and 3) a definitely satisfactory
outcome for patients with their first episode of recur-
rent disease, without significant differences between
patients with early or late first recurrence.
The current analysis was performed on 102 pa-
tients who were treated with HDS chemotherapy from
1993 to 2000. Although HDS chemotherapy was the
standard treatment for the rescue of patients with
refractory/recurrent HL in most participating centers,
a selection bias in the patient population cannot be
ruled out. However, the most substantial risk factors,
such as advanced disease stage, systemic symptoms,
and extralymph node disease at salvage therapy, oc-
FIGURE 4. Estimated event-free survival according to disease status after
patients received high-dose chemotherapy prior to autograft comparing pa-
tients who achieved complete remission (n  42 patients) with patients who
achieved partial remission (n  36 patients) or had no response (n  14
patients). Patients who achieved complete remission had a significantly better
outcome compared with patients who achieved partial remission (P  0.0007)
and patients who had no response (P  0.0001).
TABLE 4
Univariate Analysis
Parametera
No. of
patients
Three-yr
OS
projection
(%) P value
Three-yr
EFS
projection
(%) P value
Age
 40 yrs 72 67 — 58 —
 40 yrs 29 68 0.43 48 0.58
Gender
Female 46 65 — 54 —
Male 56 70 0.62 56 0.61
Stage
I–II 41 59 — 53 —
III–IV 60 73 0.55 56 0.89
BM involvement
No 90 68 — 56 —
Yes 11 63 0.12 45 0.41
Bulky disease
No 71 71 — 58 —
Yes 30 58 0.30 51 0.63
Extralymph node involvement
No 60 69 — 61 —
Yes 41 65 0.13 46 0.16
Previous radiotherapy
No 53 65 — 54 —
Yes 49 70 0.60 56 0.86
B symptoms
No 58 82 — 70 —
Yes 43 48 0.0001 34 0.0001
Disease status
First recurrence 58 79 — 65 —
 First recurrence 19 68 — 52 —
Refractory 24 41 0.003 33 0.01b
OS: overall survival; EFS: event free survival; BM: bone marrow.
a Parameters include clinical variables at the time patients received high-dose, sequential chemother-
apy.
b Patients with refractory disease versus patients in first recurrence and patients later than first
recurrence.
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curred with the same frequency reported in other
studies on HDT. In addition, most patients had re-
ceived highly effective chemotherapy regimens prior
to salvage HDS chemotherapy, including ABVD or
other multiple-drug combination schemes.31–34 Thus,
our patients had the clinical presentation observed
commonly in patients with refractory or recurrent
HL.39
The feasibility of HDS chemotherapy was among
the primary endpoints of the study. Indeed, the regi-
men proved to be feasible, with 90% of patients com-
pleting the whole program. In addition, most patients
were able to mobilize and collect PBPC amounts ad-
equate for autografting, and only 4 of 101 evaluable
patients showed no sign of mobilization. It is now a
common policy to use blood-derived hemopoietic
progenitors for autotransplantation in the treatment
of patients with HL. However, few single-center stud-
ies have detailed the extent of PBPC mobilization in
patients with HL who were not pretreated heavily.17,18
Our results are in line with those reports and confirm
that PBPC mobilization and collection as part of the
treatment of patients with refractory or recurrent HL is
an easily reproducible approach.
HDS chemotherapy also had good tolerability.
There were five treatment-related deaths, four deaths
from complications related to secondary malignan-
cies, and one death due to unspecified causes 2– 6
years after HDS chemotherapy. Even when those five
events were included among late toxic events, the
overall treatment-related mortality (TRM) rate was on
the order of 9.8%. This is in line with the 9 –15% TRM
rates reported by the Autologous Blood and Marrow
Transplant Registry and in other retrospective, multi-
center studies.13,14,19 The incidence of secondary ma-
lignancies was almost within the commonly expected
range, with five patients developing myelodysplastic
syndrome/AML and one patient developing colorectal
carcinoma. In fact, an overall incidence rate for sec-
ondary tumors ranging between 4% and 8% has been
reported after HDT and autograft in patients with
lymphoid malignancies.40 – 42 All patients who devel-
oped secondary malignancies had received radiother-
apy as part of their first-line therapy or at the time they
developed recurrent disease. In addition, it should be
noted that four of six secondary malignancies oc-
curred among patients who had to be retreated once
or several times for recurrent disease after they re-
ceived HDS chemotherapy. The absence of total body
irradiation in our preparative regimen and the small
number of patients who had received MOPP or a
MOPP-containing regimen as induction therapy may
have reduced their risk of developing secondary ma-
lignancy. Nevertheless, a prolonged follow-up will be
required to evaluate properly the risk of developing
secondary malignancies in this patient population.
The outcome was extremely favorable for the 59
patients who received HDS chemotherapy for their
first episode of recurrent disease, with an estimated
63% EFS rate at 5 years. Similar results were reported
recently by the Sloan-Kettering group using an ap-
proach analogous to HDS chemotherapy, including
intense debulking with two courses of combined ifos-
famide, carboplatin, and etoposide followed by HDT
with PBPC autograft.18 In that single-center study, an
estimated 68% EFS projection was recorded in 56 pa-
tients with chemosensitive disease who completed the
whole program. Thus, the combined use of intensive
debulking with HDT and PBPC autografting seems to
produce major improvements in the long-term out-
come of patients with nonrefractory HL who require
salvage treatment due to failure after induction ther-
apy. The observation that patients who achieve CR
prior to autograft had a significantly better outcome
compared with patients who did not achieve CR pro-
vides further support for the use of intensive chemo-
therapy as debulking before autograft.
Prolonged disease free survival in patients with
HL who experienced their first recurrence after they
received combined, intensive debulking and HDT also
was observed in a French study.19 In that study, the
treatment pattern was far from uniform. Approxi-
mately 60% of patients received varying numbers of
chemotherapy courses with combined sodium mer-
captoethanesulfonate, ifosfamide, novantrone, and
etoposide; whereas the remaining patients received
several chemotherapy courses. In addition, most pa-
tients had a single autograft, generally performed with
BEAM; whereas a minority of patients had a tandem
autograft, and three patients underwent allogeneic
transplantation. Finally, in the French study, treat-
ment feasibility was inadequate, with approximately
40% of patients unable to complete the final autograft-
ing phase. Our program was much more uniform. All
TABLE 5
Relative Risk in Multivariate Analysis
Characteristic
OS as endpoint
P value
EFS as
endpoint
P valueRR 95% CI RR 95% CI
Status at HDS
Refractory 3.80 1.4–10.0 0.008 2.47 1.1–5.5 0.03
B symptoms 3.89 1.7–8.9 0.001 2.76 1.4–5.4 0.003
OS: overall survival; EFS: event free survival: RR: risk ratio; 95% CI: 95% confidence interval; HDS:
high-dose sequential chemotherapy.
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of our patients underwent the same debulking treat-
ment, and 90% of patients had the planned single
autograft, mostly with the mitoxantrone/L-PAM con-
ditioning regimen. Thus, our observation of prolonged
disease free survival in patients at the time they first
developed recurrent HL was the result of a well-de-
fined and highly feasible treatment strategy.
The results obtained in patients who had two or
more episodes of recurrent disease confirmed the fea-
sibility of using HDS chemotherapy to treat patients
after multiple recurrences. A favorable outcome also
was observed; although, in these patients, the EFS was
not as favorable as the OS. Indeed, despite the prom-
ising survival curve, the high incidence of secondary
malignancies and the reduced chances of long-term
EFS suggest the use of HDS chemotherapy earlier, at
the time of the first treatment failure, rather than after
multiple recurrences. However, the number of pa-
tients in the group with multiple episodes of recurrent
disease was too small to draw any definite conclu-
sions.
The benefit of HDS chemotherapy was less evi-
dent in the 24 patients who had refractory disease.
Low efficacy or no efficacy has been noted in several
studies of HDT as salvage treatment for patients with
refractory HL.13,14,17,39 The 5-year EFS rate of 33% ob-
served in our series is among the best results reported
to date in these patients who respond poorly. Never-
theless, other approaches should be considered to
improve the prognosis of patients with refractory HL.
Antibody-based chemoimmunotherapy is among the
most promising, novel treatment strategies.43 In the
alternative, standard or reduced-intensity allogeneic
transplantation may be investigated, at least in
younger patients who have a human lymphocyte an-
tigen-compatible donor.44,45
Presentation with B symptoms also was predictive
of a poor outcome in the current study, similar to
other reports,10,18,19 whereas none of the other clinical
features that were proposed as strong predictors of
outcome (i.e., age, disease stage, bulky disease, BM or
other extralymph node involvement, and duration of
first CR) were significantly prognostic. There was no
significant difference in OS and EFS between patients
with early or late first recurrence, whereas other stud-
ies have found a significantly poorer outcome for pa-
tients with early recurrence.7,9,12,18 Our finding may
have been due to the fact that our centers usually
perform a restaging 1–2 months after induction. This
may imply a strict definition of first CR, with the
exclusion of patients who have a transient response
and early postchemotherapy disease progression. In
the alternative, the potent antitumor activity of HDS
chemotherapy may have improved markedly the out-
come of patients who developed recurrent disease
within 1 year after they achieved CR and abolished
their adverse prognosis.
Thus, this multicenter study provides further evi-
dence of the efficacy of HDT as rescue therapy for
patients with HL and supports the use of intensive
debulking prior to PBPC autografting to maximize its
therapeutic benefit. The intensive regimen of bleomy-
cin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine, and prednisone (BEACOP) has been proposed
as a very effective induction treatment for patients
with high-risk HL.46 However, it has not been demon-
strated that salvage regimens are as feasible or as
effective after BEACOP as they are after less intensive,
conventional regimens. To address this issue, a ran-
domized trial of ABVD compared with BEACOP, both
coupled with an HDS-like salvage program, in patients
who do not respond to induction therapy is underway
at IIL centers.
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